Loading...
•
Sep 30, 2022
Gossamer Bio Q3 2022 Earnings Report
Announced third quarter 2022 financial results and provided a business update.
Key Takeaways
Gossamer Bio reported a net loss of $59.4 million for the third quarter ended September 30, 2022, with $304.4 million in cash, cash equivalents, and marketable securities as of the same date. The company's Phase 2 TORREY Study of seralutinib is on track for topline readout in the second half of November or first half of December.
Seralutinib Phase 2 TORREY Study on track for topline readout in second half of November or first half of December.
Cash, cash equivalents & marketable securities were $304 million as of September 30, 2022.
R&D expenses were $44.5 million for the quarter ended September 30, 2022.
Net loss for the quarter ended September 30, 2022, was $59.4 million, or $0.65 per share.
Gossamer Bio
Gossamer Bio
Forward Guidance
Gossamer Bio expects its current cash, cash equivalents and marketable securities, and access to its debt facility, will be sufficient to fund its operating and capital expenditures into the second quarter of 2024.